Your browser doesn't support javascript.
loading
Delabeling of allergy to beta-lactam antibiotics in hospitalized patients: a prospective study evaluating cost savings.
Sobrino-García, Miriam; Muñoz-Bellido, Francisco J; Moreno-Rodilla, Esther; Martín-Muñoz, Rita; García-Iglesias, Aránzazu; Dávila, Ignacio.
Afiliación
  • Sobrino-García M; Allergy Service, University Hospital of Salamanca, Salamanca, Castilla y León, Spain.
  • Muñoz-Bellido FJ; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Castilla y León, Spain.
  • Moreno-Rodilla E; Allergy Service, University Hospital of Salamanca, Salamanca, Castilla y León, Spain. fjmbellido@saludcastillayleon.es.
  • Martín-Muñoz R; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Castilla y León, Spain. fjmbellido@saludcastillayleon.es.
  • García-Iglesias A; Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Castilla y León, Spain. fjmbellido@saludcastillayleon.es.
  • Dávila I; Red de Enfermedades Inflamatorias - Instituto de Salud Carlos III, Madrid, Comunidad de Madrid, Spain. fjmbellido@saludcastillayleon.es.
Int J Clin Pharm ; 46(5): 1067-1075, 2024 Oct.
Article en En | MEDLINE | ID: mdl-38642250
ABSTRACT

BACKGROUND:

Patients with a penicillin allergy label are at risk of an associated increase in adverse antibiotic events and hospitalization costs.

AIM:

We aimed to study the economic savings derived from the correct diagnosis and delabeling inpatients with suspected beta-lactam allergy, considering the acquisition cost of antimicrobials prescribed during a patient's hospital stay.

METHOD:

We prospectively evaluated patients admitted to the University Hospital of Salamanca who had been labeled as allergic to beta-lactams and performed a delabeling study. Subsequently, cost differences between antibiotics administered before and after the allergy study and those derived from those patients who received alternative antibiotics during admission and those who switched to beta-lactams after the allergy study were calculated.

RESULTS:

One hundred seventy-seven inpatients labeled as allergic to beta-lactams underwent a delabeling study; 34 (19.2%) were confirmed to have allergy to beta-lactams. Of the total number of patients, 136 (76.8%) received antibiotics during their hospitalization, involving a mean (SD) cost of €203.07 (318.42) and a median (IQR) cost of €88.97 (48.86-233.56). After delabeling in 85 (62.5%) patients, the antibiotic treatment was changed to beta-lactams. In this group of patients, the mean cost (SD) decreased from €188.91 (351.09) before the change to 91.31 (136.07) afterward, and the median cost (IQR) decreased from €72.92 (45.82-211.99) to €19.24 (11.66-168). The reduction was significant compared to the median cost of patients whose treatment was not changed to beta-lactams (p<0.001).

CONCLUSION:

Delabeling hospitalized patients represents a cost-saving measure for treating patients labeled as allergic to beta-lactams.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ahorro de Costo / Beta-Lactamas / Hipersensibilidad a las Drogas / Hospitalización / Antibacterianos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Clin Pharm Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ahorro de Costo / Beta-Lactamas / Hipersensibilidad a las Drogas / Hospitalización / Antibacterianos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Clin Pharm Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos